Breaking down the breakpoints: rationale for the 2022 Clinical and Laboratory Standards Institute revised piperacillin-tazobactam breakpoints against …
PD Tamma, PNA Harris, AJ Mathers… - Clinical Infectious …, 2023 - academic.oup.com
Piperacillin-tazobactam (PTZ) is one of the most common antibiotics administered to
hospitalized patients. Its broad activity against gram-negative, gram-positive, and anaerobic …
hospitalized patients. Its broad activity against gram-negative, gram-positive, and anaerobic …
Evaluation of Piperacillin-Tazobactam Testing against Enterobacterales by the Phoenix, MicroScan, and Vitek2 Tests Using Updated Clinical and Laboratory …
C Manuel, R Maynard, A Abbott, K Adams… - Journal of clinical …, 2023 - Am Soc Microbiol
ABSTRACT In 2022, the Clinical and Laboratory Standards Institute (CLSI) updated
piperacillin-tazobactam (TZP) breakpoints for Enterobacterales, based on substantial data …
piperacillin-tazobactam (TZP) breakpoints for Enterobacterales, based on substantial data …
Piperacillin/tazobactam Susceptibility Test Interpretive Criteria for Enterobacterales: Recommendations from the United States Committee on Antimicrobial …
TP Lodise, SM Bhavnani, PG Ambrose… - Clinical Infectious …, 2024 - academic.oup.com
The in vitro susceptibility testing interpretive criteria (STIC) for TZP against Enterobacterales
were recently updated by the Food and Drug Administration (FDA), Clinical & Laboratory …
were recently updated by the Food and Drug Administration (FDA), Clinical & Laboratory …
Building a better test for piperacillin-tazobactam susceptibility testing: would that it were so simple (it's complicated)
A Henderson, R Humphries - Journal of clinical microbiology, 2020 - Am Soc Microbiol
In this issue of the Journal of Clinical Microbiology, S. García-Fernandez, Y. Bala, T.
Armstrong, M. Garcia-Castillo, et al.(J Clin Microbiol 58: e01042-19, 2020, https://doi …
Armstrong, M. Garcia-Castillo, et al.(J Clin Microbiol 58: e01042-19, 2020, https://doi …
Multicenter evaluation of the new Etest gradient diffusion method for piperacillin-tazobactam susceptibility testing of Enterobacterales, Pseudomonas aeruginosa, and …
S García-Fernández, Y Bala, T Armstrong… - Journal of clinical …, 2020 - Am Soc Microbiol
ABSTRACT Piperacillin-tazobactam (P/T) is a β-lactam–β-lactamase inhibitor combination
frequently used in the hospital setting. Etest is a gradient diffusion method that represents an …
frequently used in the hospital setting. Etest is a gradient diffusion method that represents an …
Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested …
DM Johnson, DJ Biedenbach, RN Jones - Diagnostic microbiology and …, 2002 - Elsevier
The in vitro activity of piperacillin/tazobactam and several comparison broad-spectrum
compounds was assessed against recent clinical isolates of Gram-positive and-negative …
compounds was assessed against recent clinical isolates of Gram-positive and-negative …
Impact of the recent clinical and Laboratory Standards Institute breakpoint changes on the Antimicrobial Spectrum of Aminoglycosides and the activity of Plazomicin …
HS Sader, RE Mendes, JH Kimbrough… - Open Forum …, 2023 - academic.oup.com
Abstract Background The Clinical and Laboratory Standards Institute (CLSI) lowered the
Enterobacterales-susceptible/-resistant breakpoints for amikacin in 2023 from≤ 16/≥ 64 …
Enterobacterales-susceptible/-resistant breakpoints for amikacin in 2023 from≤ 16/≥ 64 …
Effects of Breakpoint Changes on Carbapenem Susceptibility Rates ofEnterobacteriaceae: Results from the SENTRY Antimicrobial Surveillance Program, United …
RP Rennie, RN Jones - Canadian Journal of Infectious …, 2014 - Wiley Online Library
In the absence of clinical resistance, breakpoints for many antimicrobial agents are often set
high. Clinical failures following use of the agents over time requires re‐evaluation of …
high. Clinical failures following use of the agents over time requires re‐evaluation of …
Comparison of four antimicrobial susceptibility testing methods to determine the in vitro activities of piperacillin and piperacillin-tazobactam against clinical isolates of …
JA Karlowsky, MK Weaver, C Thornsberry… - Journal of clinical …, 2003 - Am Soc Microbiol
Susceptibility to piperacillin was similar to that to piperacillin-tazobactam (< 1% difference)
for 6,938 isolates of Enterobacter aerogenes and 13,954 isolates of Enterobacter cloacae …
for 6,938 isolates of Enterobacter aerogenes and 13,954 isolates of Enterobacter cloacae …
Activity of ertapenem/zidebactam (WCK 6777) against problem Enterobacterales
S Mushtaq, P Garello, A Vickers… - Journal of …, 2022 - academic.oup.com
Background Secondary healthcare will remain pressured for some years, both because
SARS-CoV-2 will circulate as a nosocomial pathogen, and owing to backlogs of patients …
SARS-CoV-2 will circulate as a nosocomial pathogen, and owing to backlogs of patients …
相关搜索
- piperacillin tazobactam susceptibility testing
- piperacillin tazobactam clinical isolates
- piperacillin tazobactam tract infections
- piperacillin tazobactam organism populations
- piperacillin tazobactam spectrum update
- piperacillin tazobactam multicenter evaluation
- piperacillin tazobactam pseudomonas aeruginosa